Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115635
Status:
COMPLETED
Last Update Posted:
2007-10-02
First Post:
2005-06-23
Brief Title:
Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
Sponsor:
Herlev Hospital
Organization:
Herlev Hospital
Study Overview
Official Title:
A Phase III Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer and evaluate this dose with respect to efficacy and toxicity in a phase II trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2004-002353-31 | None | None | None |